{
    "nct_id": "NCT06864988",
    "official_title": "A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration",
    "inclusion_criteria": "* ≥50 years of age at time of consent\n* Treatment naïve MNV secondary to nAMD in the study eye\n* Active subfoveal MNV or juxtafoveal/ extrafoveal MNV with a subfoveal component (where activity is defined as evidence of SRF, IRF, subretinal hyperreflective material, or leakage) identified by fluorescein angiography (FA) or spectral domain optical coherence tomography (SD-OCT), in the study eye, at the Screening Visit confirmed by the Reading Center\n* Demonstrated clinical response to aflibercept and functional stability in the study eye as confirmed by the Reading Center\n* BCVA between 25 and 78 ETDRS letters, inclusive (20/320-20/32 Snellen equivalent) in the study eye at the Screening Visit\nHealthy volunteers allowed\nMust have minimum age of 50 Years",
    "exclusion_criteria": "Ocular Conditions:\n\n* MNV due to causes other than nAMD in either eye (Fibrosis, atrophy, or subretinal hemorrhage in the foveal central subfield (1 mm diameter))\n* History of retinal detachment in the study eye\n* History of or presence of active inflammation in either eye\n* Glaucoma or intraocular hypertension requiring more than 2 topical medications for control\n\nSystemic Conditions and Considerations:\n\n* Major illness or major surgical procedure in the 28 days prior to the Screening Visit\n* Uncontrolled blood pressure\n* Acute coronary syndrome, myocardial infarction or coronary artery revascularization, cerebrovascular accident, transient ischemic attack within 6 months of the Screening Visit\n* History of autoimmune condition that may predispose to the development of uveitis",
    "miscellaneous_criteria": ""
}